ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on the unaudited financial results for the quarter and half year ended on September 30, 202210-11-2022
10-11-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Outcome Of Board Meeting
Unaudited financial results (standalone and consolidated) for the quarter and half year ended on September 30, 202210-11-2022
USFDA approves Zydus Lifesciences' generic hypertension drug
Zydus Lifesciences' generic hypertension drug, Bisoprolol Fumarate and Hydrochlorothiazide, received approval from USFDA08-11-2022
Zydus gets establishment inspection report from USFDA for Moraiya plant
Zydus Lifesciences on Monday said it has received an establishment inspection report from the US health regulator for its formulations manufacturing facility in Moraiya near Ahmedabad. The US Food and Drug Administration (USFDA) inspected the facility from July 26 to August 5, 2022, which concluded with four observations. "The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)," it added. The USFDA issues an establishment inspection report (EIR) to an establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection. Shares of Zydus Lifesciences were trading 2.51 per cent up at Rs 450.85 apiece on the BSE.07-11-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has scheduled investor interaction through a teleconference call at 3:00 p.m. (IST) on Thursday, November 10, 2022, post announcement of unaudited financial results for the quarter and half year ended on September 30, 2022. Details for joining the call are attached herewith.02-11-2022
ZYDUS WELLNESS LTD.-$ - 531335 - Board Meeting Intimation for Notice For The Meeting Of Board Of Directors
ZYDUS WELLNESS LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 ,inter alia, to consider and approve unaudited financial results for the quarter and half year ended on September 30, 2022.01-11-2022
Zydus Lifesciences gets USFDA nod for generic Valbenazine, Roflumilast
Zydus Lifesciences on Monday said it has got tentative approval from the US health regulator to market its generic versions of Valbenazine capsules and Roflumilast tablets. Valbenazine capsules are indicated for the treatment of tardive dyskinesia (uncontrolled movement of body parts such as face and tongue) while Roflumilast tablets are used for reducing risk of chronic obstructive pulmonary disease in severely affected patients associated with chronic bronchitis and a history of exacerbations. The tentative approval granted by the US Food and Drug Administration (USFDA) to the company's arm Zydus Worldwide DMCC to market Valbenazine capsules is for strengths 40 mg, 60 mg, and 80 mg, Zydus Lifesciences said in a regulatory filing. As per IQVIA MAT August 2022 data, Valbenazine capsules had annual sales of USD 781 million in the US. Zydus further said its US subsidiary Zydus Pharmaceuticals (USA) Inc has also received tentative approval from the USFDA to market Roflumilast tablets17-10-2022
Hot Stocks | Sun TV Network, Zydus Wellness can give up to 11% return in short term, here's why
Zydus Wellness has recently given a triangle pattern breakout near its long term support area on the weekly timeframe. The 200 EMA is at Rs 1,680 and the stock is comfortably sustaining above it, which can be used as a confluence to the bullish view.13-10-2022
Back-to-back US FDA approvals boost Zydus Lifesciences; stock at 8-month high
The US accounts for 40 percent of the company's revenue, which is why each FDA approval is a positive10-10-2022
Mehul Kothari recommends these 2 stocks on 'Symmetrical Triangle' breakout
According to the technical analyst from Anand Rathi, Godfreh Phillips can jump to Rs 1,320, while Zydus Wellness can be bought for a target of Rs 1,860.07-10-2022